Ethan Knowlden is a senior attorney with more than twenty-five years of domestic and international experience in business development, licensing, litigation, real estate, commercial transactions, corporate, and securities matters and healthcare compliance for medical device/life science and other technology companies.
He has handled a broad range of transactions for established, multi-national commercial firms as well as start-up entities, including technology transfer, multi-party cross licensing, and all forms of development, manufacturing, supply, sales, and distribution arrangements. He has also led strategic transaction negotiation and due diligence teams.
In 2017, Mr. Knowlden served as SVP, General Counsel & Secretary of Accela, Inc., a provider of cloud-based software solutions, leading the Legal function through the company’s $750-million Private Equity acquisition by Berkshire Partners. From 2013 to 2016 he served as SVP, General Counsel & Secretary at Complete Genomics, Inc., a provider of next-generation sequencing technology and services. From 2000 to 2012, he served in various capacities at Novartis Vaccines and Diagnostics, Inc. and its predecessor, Chiron Corporation, most recently as VP of Business Development and Licensing, Corporate Counsel.
His experience includes seven years in private practice as a corporate and securities specialist with Hughes & Luce LLP (now K&L Gates) and Gardere & Wynne (now Foley Gardere), both Dallas-based law firms. Mr. Knowlden began his career as a Financial Analyst in the New York office of The First Boston Corporation (now Credit Suisse).
Mr. Knowlden received his BA in Art and Economics from Wesleyan University and his JD from the University of Virginia.